Irinotecan Hydrochloride Injection
Product Images NDC 50742-402

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Irinotecan Hydrochloride (NDC 50742-402). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ingenus Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

27b29c94 6029 4c8d 9cc9 845b2d5cb006 01

FDA Label Image

27b29c94 6029 4c8d 9cc9 845b2d5cb006 02

FDA Label Image

27b29c94 6029 4c8d 9cc9 845b2d5cb006 03

27b29c94 6029 4c8d 9cc9 845b2d5cb006 03
This is a graph for a study (Study 2) comparing the survival rate between two treatments: Irinotecan/5-FU/LV and 5-FULV. The x-axis shows the number of months after treatment, and the y-axis represents the probability of survival. The log-rank test was used to compare the two treatments.*
FDA Label Image

27b29c94 6029 4c8d 9cc9 845b2d5cb006 04

27b29c94 6029 4c8d 9cc9 845b2d5cb006 04
This is a figure showing survival data for a study (Study 7) comparing second-line Irinotecan treatment to Best Supportive Care (BSC) for patients with a certain condition. The figure displays the number of patients in each group (189 for Irinotecan and 90 for BSC), the median follow-up time (13 months), and the median survival time (9.2 months for Irinotecan and 6.5 months for BSC). Additionally, the figure shows a statistical test (log-rank) with a p-value of 0.0001 indicating a significant difference in survival between the two treatments.*
FDA Label Image

27b29c94 6029 4c8d 9cc9 845b2d5cb006 05

FDA Label Image

27b29c94 6029 4c8d 9cc9 845b2d5cb006 06

FDA Label Image

27b29c94 6029 4c8d 9cc9 845b2d5cb006 07

FDA Label Image

27b29c94 6029 4c8d 9cc9 845b2d5cb006 08

FDA Label Image

27b29c94 6029 4c8d 9cc9 845b2d5cb006 09

27b29c94 6029 4c8d 9cc9 845b2d5cb006 09
This is a product description of Irinotecan Hydrochloride Injection, USP, a cytotoxic agent used for intravenous use. The 100mg/5mL single-dose vial must be diluted before use. The product is manufactured by Ingenus Pharmaceuticals and comes in a 2mg/mL concentration, and should be stored properly to prevent freezing. Contact information for the manufacturer is provided.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.